Literature DB >> 9497864

Gaucher's disease: genetic counselling and population screening.

E Levy-Lahad1, A Zimran.   

Abstract

Genetic counselling for Gaucher's disease requires a comprehensive approach, including accurate diagnosis at both the enzymatic and molecular levels, and assessment of disease severity. These goals are particularly challenging given the great allelic and phenotypic heterogeneity encountered in this disorder. Counselling should address the specific concerns of the counsellee, which may be related to evaluation of an affected person, or to reproductive options in couples at risk. Advances in both diagnosis and treatment have led to increased ascertainment of cases and carriers through population based screening, rather than through affected probands, raising new ethical and medical dilemmas. This chapter outlines practical issues in counselling for the various forms of Gaucher's disease, based on current data and experience.

Entities:  

Mesh:

Year:  1997        PMID: 9497864     DOI: 10.1016/s0950-3536(97)80040-6

Source DB:  PubMed          Journal:  Baillieres Clin Haematol        ISSN: 0950-3536


  4 in total

1.  Disease severity in sibling pairs with type 1 Gaucher disease.

Authors:  Deborah Elstein; Ayelet Gellman; Gheona Altarescu; Aya Abrahamov; Irith Hadas-Halpern; Mici Phillips; Maya Margalit; Ehud Lebel; Menachem Itzchaki; Ari Zimran
Journal:  J Inherit Metab Dis       Date:  2010-01-05       Impact factor: 4.982

2.  Non-pseudogene-derived complex acid beta-glucosidase mutations causing mild type 1 and severe type 2 gaucher disease.

Authors:  M E Grace; P Ashton-Prolla; G M Pastores; A Soni; R J Desnick
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

3.  Receiving enzyme replacement therapy for a lysosomal storage disorder: a preliminary exploration of the experiences of young patients and their families.

Authors:  R Freedman; M Sahhar; L Curnow; J Lee; H Peters
Journal:  J Genet Couns       Date:  2013-03-28       Impact factor: 2.537

Review 4.  The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.

Authors:  T M Cox; J M F G Aerts; G Andria; M Beck; N Belmatoug; B Bembi; R Chertkoff; S Vom Dahl; D Elstein; A Erikson; M Giralt; R Heitner; C Hollak; M Hrebicek; S Lewis; A Mehta; G M Pastores; A Rolfs; M C Sa Miranda; A Zimran
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.